The 2026 World Governments Summit (WGS 2026) was held in Dubai, United Arab Emirates from 3 to 5 February 2026 under the theme "Shaping Future Governments." The Summit brought together government representatives from more than 150 countries and regions, over 35 heads of state and government, and more than 6,000 participants to discuss global governance and leadership, economic prosperity and emerging opportunities, as well as future cities and demographic change.

CanSino Biologics Inc. ("CanSinoBIO") participated in the Summit for the second consecutive year as the only vaccine company invited globally. Dr. Xuefeng Yu, Chairman and Chief Executive Officer of CanSinoBIO, and Ms. Jeanne Wang, Chief Commercial Officer, attended the Summit and engaged in a series of exchanges with global policymakers and partners.

Dr. Xuefeng Yu, Chairman and Chief Executive Officer of CanSinoBIO(right), and Ms. Jeanne Wang, Chief Commercial Officer, attended the WGS2026.

During the Summit, Dr. Yu was invited to speak at the "New Silk Road Forum", where he shared CanSinoBIO's experience in addressing global public health challenges through innovation. He emphasized the importance of strengthening international collaboration to ensure that scientific breakthroughs are translated into accessible solutions and benefit broader populations more equitably.

Advancing Vaccine Innovation to Support Global Public Health

Dr. Xuefeng Yu, Chairman and Chief Executive Officer of CanSinoBIO, speaks at the "New Silk Road Forum".

Dr. Yu noted that in the life sciences, innovation goes beyond technological breakthroughs; it requires the effective translation of scientific achievements into accessible and scalable solutions that can deliver tangible health benefits across different countries and regions. Guided by its mission to provide innovative, high-quality and affordable vaccines worldwide, CanSinoBIO continues to advance research and development with a focus on unmet public health needs.

The company's rapid response to the COVID-19 pandemic illustrates this approach. Leveraging its leading technology platforms, CanSinoBIO shortened development timelines and expanded technological applications across multiple disease areas. Its recombinant COVID-19 vaccine (adenovirus type 5 vector) was among the earliest vaccines included on the World Health Organization's Emergency Use Listing and has supported immunization programs in multiple countries. In 2022, CanSinoBIO's inhaled COVID-19 vaccine received emergency use authorization in China, becoming the world's first inhaled COVID-19 vaccine.

Building on the inhalation technology platform, CanSinoBIO is extending its application to major disease areas such as tuberculosis. In November 2025, the company initiated a Phase I clinical trial of its inhaled tuberculosis vaccine in Indonesia. By inducing mucosal immunity in the lungs through inhaled delivery, the candidate vaccine is expected to provide a new technical pathway for tuberculosis prevention and control, demonstrating the value of platform-based innovation in addressing the needs of high-burden regions.

In the "final mile" of global polio eradication, public health systems face increasingly complex challenges. CanSinoBIO's recombinant polio vaccine (VLP-Polio), based on a novel virus-like particle assembly technology, does not use live virus in the manufacturing process, significantly reducing biosafety risks at source. The World Health Organization has recommended the VLP-Polio as a future candidate for polio eradication. The platform is also compatible with combination vaccine development, which may help reduce the number of injections, simplify immunization schedules, and improve coverage and compliance. Clinical studies conducted in countries including Australia and Indonesia are accelerating the translation of this innovation into practice, contributing to greater resilience and efficiency in global immunization systems.

In addition, CanSinoBIO has made steady progress in the development of its recombinant pneumococcal protein-based vaccine (PBPV). The vaccine is expected to provide broader serotype coverage than existing products, helping to mitigate the risk of serotype replacement. Its streamlined manufacturing process supports large-scale production and quality control. Encouraging preliminary results from Phase I clinical trials suggest that the vaccine could become a valuable complement to existing pneumococcal vaccines, offering new options for sustainable immunization programs in resource-limited settings.

Expanding Global Footprint Through Partnerships

Dr. Yu emphasized that innovation alone is not sufficient to address global public health challenges. Global expansion requires building trust, aligning with local regulatory systems, and working closely with local partners to co-create sustainable solutions. In recent years, CanSinoBIO has continued to strengthen its international presence through collaborations with partners in countries including Indonesia, Malaysia, Saudi Arabia and Brazil.

In Indonesia, the company is advancing the development of its inhaled tuberculosis vaccine and the overseas launch and bulk supply of Menhycia®, its quadrivalent meningococcal conjugate vaccine, while conducting clinical studies to expand the applicable population and strengthen the product’s commercialization foundation. In Saudi Arabia and the Middle East and North Africa region, CanSinoBIO is promoting product market access and commercialization while exploring opportunities for joint research and localized manufacturing. In Malaysia, alongside the construction of a vaccine fill-and-finish facility, the company is collaborating with local institutions on the development of multivalent mRNA influenza vaccines to support global influenza prevention and control efforts.

Ms. Jeanne Wang, Chief Commercial Officer of CanSinoBIO, said that the World Governments Summit provides an important platform for strengthening global collaboration. She noted that CanSinoBIO will continue to expand its international presence, enhance cooperation with governments, international organizations and local partners, and explore diversified collaboration models to accelerate access to innovative vaccines in more countries and regions in support of global public health.

Building Sustainable Global Partnerships Based on Trust

Dr. Yu highlighted that earning the trust of governments and partners worldwide depends on delivering on commitments and advancing science with integrity. Innovation must align with regulatory standards and local public health priorities, while being implemented through close collaboration with local partners to establish sustainable cooperation models. By integrating technological innovation with regulatory frameworks and local resources and capabilities, scientific breakthroughs can be translated into long-term, meaningful impact across borders.

Looking ahead, CanSinoBIO will continue to advance innovation under the frameworks of the World Health Organization and national regulatory authorities. The company will further deepen collaboration with governments, international organizations, industry partners and local institutions, strengthen quality management, supply chain development and localization capabilities, and promote broader access to innovative vaccines in more countries and regions to better serve global public health needs.